- Sales growth for the past 3 years has been at 25.22 %.
- Having highest market cap in the pharma industry at Rs 140564.43 Cr.
- The compounded profit growth of the past 5 years at been at 23.02%.
Particulars | Info |
Current Price: | 585.85 |
52 weeks High / Low | 608.55 / 433.15 |
Market Cap: | 140,564 Cr. |
Stock P/E: | 41.38 |
Face Value | 1 |
ROCE: | 21.01 % |
Book Value: | 163.58 |
Dividend Yield: | 0.60 % |
Sales Growth (3Yrs): | 25.22 % |
Listed on | BSE and NSE |
ROE: | 19.86 % |
Holder's Name | % Shareholding |
Promoters | 54.38% |
Foreign Institutions | 16.40% |
Banks and Mutual Funds | 8.41% |
Financial Institutions | 8.17% |
General Public | 6.97% |
Others | 5.67% |
S.No. | Name | CMP Rs. | P/E | Mar Cap Rs.Cr. | Div Yld % | NP Qtr Rs.Cr. | Qtr Profit Var % | Sales Qtr Rs.Cr. | Qtr Sales Var % | ROCE % |
1 | Piramal Enterp. | 2,794 | 10 | 50,465 | 1 | -69.81 | -33.36 | 2902.49 | 29.24 | 28.33 |
2 | Sun Pharma.Inds. | 586 | 41 | 140,564 | 1 | 1528.99 | 10.35 | 6977.1 | -2.24 | 21.01 |
3 | Unichem Labs. | 236.4 | 0.66 | 1662.91 | 2.11 | -20.65 | -1476.67 | 201.43 | 42.54 | -15.38 |
4 | Aurobindo Pharma | 623.15 | 15.07 | 36510.83 | 0.4 | 528.51 | -0.74 | 4049.09 | 11.19 | 27.6 |
5 | Cadila Health. | 377.3 | 21.75 | 38625.81 | 0.93 | 590.8 | 53.26 | 3250.2 | 31.77 | 21.04 |
6 | Lupin | 886 | 25.33 | 40060.78 | 0.56 | -777.6 | 42.48 | 4033.83 | -5.16 | 11.24 |
7 | Claris Lifescien | 396.55 | 1.37 | 2163.88 | 0.5 | -317.43 | -1809.37 | 2.07 | -54.51 | -10.91 |
Mar 2018 | Dec 2017 | Sep 2017 | Jun 2017 | Mar 2017 | Dec 2016 | |
Sales | 6,977 | 6,653 | 6,650 | 6,208 | 7,136 | 7,925 |
Expenses | 5,293 | 5,199 | 5,274 | 6,063 | 5,589 | 5,471 |
Operating Profit | 1,683 | 1,453 | 1,375 | 145 | 1,547 | 2,453 |
OPM % | 24.13% | 21.84% | 20.68% | 2.34% | 21.68% | 30.95% |
Other Income | 302 | 129 | 254 | 151 | 224 | 122 |
Depreciation | 455 | 339 | 358 | 346 | 338 | 306 |
Interest | 155 | 95 | 157 | 109 | 44 | 166 |
Profit before tax | 1,375 | 1,147 | 1,114 | -158 | 1,388 | 2,102 |
Tax | -176 | 748 | 111 | 161 | 44 | 372 |
Net Profit | 1,528 | 400 | 1,001 | -322 | 1,385 | 1,721 |
Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | |
Sales | 31,578 | 28,487 | 27,392 | 16,080 | 11,130 | 8,019 |
Expenses | 21,489 | 21,013 | 19,763 | 11,598 | 6,824 | 4,816 |
Operating Profit | 10,089 | 7,473 | 7,628 | 4,482 | 4,306 | 3,203 |
OPM % | 31.95% | 26.23% | 27.85% | 27.87% | 38.69% | 39.94% |
Other Income | 623 | 658 | 547 | 552 | 388 | 471 |
Interest | 399 | 523 | 578 | 44 | 43 | 28 |
Depreciation | 1,264 | 1,037 | 1,194 | 409 | 336 | 291 |
Profit before tax | 9,047 | 6,570 | 6,402 | 4,581 | 4,314 | 3,355 |
Tax | 1,211 | 913 | 914 | 702 | 845 | 313 |
Net Profit | 6,964 | 4,545 | 4,539 | 3,141 | 2,983 | 2,656 |
Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | |
Cash from Operating Activity | 7,082 | 6,685 | 5,615 | 3,959 | 3,356 | 2,234 |
Cash from Investing Activity | -4,186 | -3,949 | -1,502 | -2,176 | -2,375 | -747 |
Cash from Financing Activity | -2,285 | -1,888 | -1,186 | 506 | -664 | -544 |
Net Cash Flow | 610 | 848 | 2,926 | 2,289 | 316 | 942 |
Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | |
Share Capital | 239 | 240 | 207 | 207 | 103 | 103 |
Reserves | 36,399 | 32,741 | 25,378 | 18,317 | 14,886 | 12,132 |
Borrowings | 9,831 | 8,496 | 8,996 | 2,560 | 259 | 320 |
Other Liabilities | 15,440 | 14,463 | 14,635 | 8,298 | 5,343 | 3,945 |
Total Liabilities | 61,911 | 55,941 | 49,217 | 29,384 | 20,592 | 16,502 |
Fixed Assets | 17,675 | 15,872 | 12,682 | 6,817 | 5,647 | 3,951 |
CWIP | 2,801 | 2,175 | 2,038 | 841 | 562 | 344 |
Investments | 1,191 | 1,829 | 2,716 | 2,786 | 2,411 | 2,212 |
Other Assets | 40,243 | 36,064 | 31,780 | 18,939 | 11,971 | 9,993 |
Total Assets | 61,911 | 55,941 | 49,217 | 29,384 | 20,592 | 16,502 |
Leave A Comment?